References
- Cancer Research UK. Adoptive cell transfer. 2017 [cited 2018 Jul 27]. Available from: https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/immunotherapy/types/adoptive-cell-transfer
- National Cancer Institute. CAR T cells: engineering patients’ immune cells to treat their cancers. 2017 [cited 2018 Jul 27]. Available from: https://www.cancer.gov/about-cancer/treatment/research/car-t-cells
- Melanoma Research Alliance. Adoptive cell transfer therapy. 2017 [cited 2018 Jul 27]. Available from: https://www.curemelanoma.org/patient-eng/melanoma-treatment/therapies-in-development/adoptive-cell-transfer-therapy/
- American Cancer Society. Chimeric antigen receptor (CAR) T-cell therapy. 2017 [cited 2018 Jul 27]. Available from: https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/car-t-cell1.html.
- Hettle, R., et al. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal. Health Technol Assess. 2017;21(7):1–8.
- Saha V ALLR3: an international collaborative trial for relapsed and refractory Acute Lymphoblastic Leukaemia (ALL). 2007 [cited 2018 Jul 27]. Available from: http://journals.plos.org/plosone/article/file?type=supplementary&id=info:doi/10.1371/journal.pone.0108107.s003
- Lymphoma Action. UKALL 2011: a phase 3 trial looking at reducing side effects by changing the standard treatment for acute lymphoblastic leukaemia or lymphoblastic lymphoma in children and young people aged 1-24. [cited 2018 Jul 27]. Available from: https://lymphoma-action.org.uk/index.php/trial/ukall-2011-phase-3-trial-looking-reducing-side-effects-changing-standard-treatment-acute
- National institute for Health and Care Excellence (NICE). Technology appraisal guidance. 2018 [cited 2018 Jul 27]. Available from: https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance
- Pauwels, K., et al. Managed entry agreements for oncology drugs: lessons from the European experience to inform the future. Front Pharmacol. 2017;8(171).
- van de Vooren, K., et al. Market-access agreements for anti-cancer drugs. J R Soc Med. 2015;108(5):166–170.
- National institute for Health and Care Excellence (NICE). Patient access schemes liaison unit. 2018 [cited 2018 Jul 27]. Available from: https://www.nice.org.uk/about/what-we-do/patient-access-schemes-liaison-unit
- NHS England. Cancer drugs fund. 2018 [cited 2018 Jul 27]. Available from: https://www.england.nhs.uk/cancer/cdf/.
- National institute for Health and Care Excellence (NICE). Highly specialised technologies guidance. 2018 [cited 2018 Jul 27]. Available from: https://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-highly-specialised-technologies-guidance.
- NHS Employers. NHS terms and conditions (AfC) pay scales - Hourly. 2018 [cited 2018 Jul 27]. Available from: http://www.nhsemployers.org/your-workforce/pay-and-reward/agenda-for-change/pay-scales/hourly.